These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 34150872)

  • 21. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
    Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE
    Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic Importance of Temporal Changes in Resting Heart Rate in Heart Failure and Preserved Ejection Fraction: From the TOPCAT Study.
    Vazir A; Claggett B; Pitt B; Anand I; Sweitzer N; Fang J; Fleg J; Rouleau J; Shah S; Pfeffer MA; Solomon SD
    JACC Heart Fail; 2017 Nov; 5(11):782-791. PubMed ID: 29032132
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic Significance of Heart Rate and Beta-Blocker Use in Sinus Rhythm in Patients with Heart Failure and Preserved Ejection Fraction.
    Li S; Li X
    High Blood Press Cardiovasc Prev; 2019 Oct; 26(5):405-411. PubMed ID: 31625118
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Perturbations in serum chloride homeostasis in heart failure with preserved ejection fraction: insights from TOPCAT.
    Grodin JL; Testani JM; Pandey A; Sambandam K; Drazner MH; Fang JC; Tang WHW
    Eur J Heart Fail; 2018 Oct; 20(10):1436-1443. PubMed ID: 29893446
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of physical activity and risk of atrial fibrillation in heart failure with preserved ejection fraction.
    Zhu W; Liang W; Ye Z; Wu Y; He X; Xue R; Wu Z; Zhou Y; Zhao J; Dong Y; Liu C
    Nutr Metab Cardiovasc Dis; 2021 Jan; 31(1):247-253. PubMed ID: 33097408
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Favorable effects of statins in the treatment of heart failure with preserved ejection fraction in patients without ischemic heart disease.
    Tsujimoto T; Kajio H
    Int J Cardiol; 2018 Mar; 255():111-117. PubMed ID: 29307549
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of β-Blocker Use With Heart Failure Hospitalizations and Cardiovascular Disease Mortality Among Patients With Heart Failure With a Preserved Ejection Fraction: A Secondary Analysis of the TOPCAT Trial.
    Silverman DN; Plante TB; Infeld M; Callas PW; Juraschek SP; Dougherty GB; Meyer M
    JAMA Netw Open; 2019 Dec; 2(12):e1916598. PubMed ID: 31800067
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CHA2DS2-VASc and ATRIA Scores and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction.
    Zhu W; Wu Y; Zhou Y; Liang W; Xue R; Wu Z; Dong Y; Liu C
    Cardiovasc Drugs Ther; 2020 Dec; 34(6):763-772. PubMed ID: 32583288
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of obesity with heart failure outcomes in 11 Asian regions: A cohort study.
    Chandramouli C; Tay WT; Bamadhaj NS; Tromp J; Teng TK; Yap JJL; MacDonald MR; Hung CL; Streng K; Naik A; Wander GS; Sawhney J; Ling LH; Richards AM; Anand I; Voors AA; Lam CSP;
    PLoS Med; 2019 Sep; 16(9):e1002916. PubMed ID: 31550265
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction.
    Tromp J; Shen L; Jhund PS; Anand IS; Carson PE; Desai AS; Granger CB; Komajda M; McKelvie RS; Pfeffer MA; Solomon SD; Køber L; Swedberg K; Zile MR; Pitt B; Lam CSP; McMurray JJV
    J Am Coll Cardiol; 2019 Aug; 74(5):601-612. PubMed ID: 31370950
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Body mass index and all-cause mortality in heart failure patients with normal and reduced ventricular ejection fraction: a dose-response meta-analysis.
    Zhang J; Begley A; Jackson R; Harrison M; Pellicori P; Clark AL; Cleland JGF
    Clin Res Cardiol; 2019 Feb; 108(2):119-132. PubMed ID: 29951802
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial.
    Lewis EF; Kim HY; Claggett B; Spertus J; Heitner JF; Assmann SF; Kenwood CT; Solomon SD; Desai AS; Fang JC; McKinlay SA; Pitt BA; Pfeffer MA;
    Circ Heart Fail; 2016 Mar; 9(3):e001937. PubMed ID: 26962133
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of Malnutrition Using Geriatric Nutritional Risk Index in Heart Failure With Preserved Ejection Fraction.
    Minamisawa M; Seidelmann SB; Claggett B; Hegde SM; Shah AM; Desai AS; Lewis EF; Shah SJ; Sweitzer NK; Fang JC; Anand IS; O'Meara E; Rouleau JL; Pitt B; Solomon SD
    JACC Heart Fail; 2019 Aug; 7(8):664-675. PubMed ID: 31302049
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ankle-brachial index and incident heart failure with reduced versus preserved ejection fraction: The Multi-Ethnic Study of Atherosclerosis.
    Prasada S; Shah SJ; Michos ED; Polak JF; Greenland P
    Vasc Med; 2019 Dec; 24(6):501-510. PubMed ID: 31480898
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic importance of left ventricular mechanical dyssynchrony in heart failure with preserved ejection fraction.
    Biering-Sørensen T; Shah SJ; Anand I; Sweitzer N; Claggett B; Liu L; Pitt B; Pfeffer MA; Solomon SD; Shah AM
    Eur J Heart Fail; 2017 Aug; 19(8):1043-1052. PubMed ID: 28322009
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Prognostic value of N-terminal B-type natriuretic peptide on all-cause mortality in heart failure patients with preserved ejection fraction].
    Cao J; Jin XJ; Zhou J; Chen ZY; Xu DL; Yang XC; Dong W; Li LW; Luo J; Chen L; Fu M; Zhou JM; Ge JB
    Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Nov; 47(11):875-881. PubMed ID: 31744276
    [No Abstract]   [Full Text] [Related]  

  • 37. Impact of Sex on Ventricular-Vascular Stiffness and Long-Term Outcomes in Heart Failure With Preserved Ejection Fraction: TOPCAT Trial Substudy.
    Beale AL; Nanayakkara S; Kaye DM
    J Am Heart Assoc; 2019 Jul; 8(13):e012190. PubMed ID: 31230508
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of Cigarette Smoking on Risk for Adverse Events in Patients With Heart Failure and Preserved Ejection Fraction.
    Sandesara PB; Samman-Tahhan A; Topel M; Venkatesh S; O'Neal WT
    Am J Cardiol; 2018 Aug; 122(3):400-404. PubMed ID: 30201107
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diastolic Blood Pressure and Adverse Outcomes in the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) Trial.
    Sandesara PB; O'Neal WT; Kelli HM; Topel M; Samman-Tahhan A; Sperling LS
    J Am Heart Assoc; 2018 Feb; 7(5):. PubMed ID: 29475874
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic Implication of Liver Function Tests in Heart Failure With Preserved Ejection Fraction Without Chronic Hepatic Diseases: Insight From TOPCAT Trial.
    Liang W; He X; Wu D; Xue R; Dong B; Owusu-Agyeman M; Zhao J; Cai L; You Z; Dong Y; Liu C
    Front Cardiovasc Med; 2021; 8():618816. PubMed ID: 34055924
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.